Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR-T cells (third-generation)
- Development stage
- Unknown
- Lead developer
- Aristotle University of Thessaloniki
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR-T cells (third-generation) are autologous or allogeneic T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19. Unlike second-generation CARs, which incorporate a single costimulatory domain (typically CD28 or 4-1BB), third-generation CARs feature two costimulatory domains (such as CD28 and 4-1BB, or CD28 and TLR2) in tandem with the CD3-zeta signaling domain. This dual costimulatory design is intended to enhance T-cell activation, proliferation, and in vivo persistence, potentially improving therapeutic efficacy and durability in patients with B-cell malignancies, including leukemia and lymphoma, while maintaining a manageable safety profile.
- Other names
- third-generation CD19 CAR-Tthird-generation CD19 CAR-T cellsthird-generation CD19-directed CAR-Tthird-generation CD19-directed CAR-T cellsthird-generation CD19-targeted CAR-Tthird-generation CD19-targeted CAR-T cellsthird-generation anti-CD19 CAR-Tthird-generation anti-CD19 CAR-T cells
Beyond the preview
Go deeper on CD19 CAR-T cells (third-generation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR-T cells (third-generation).